WS #16622
As the tech sector collapses, defensive rotation is accelerating into large-cap biopharmaceuticals. Eli Lilly received a price target raise to $1,500 from Wells Fargo, and shares of major drugmakers like J&J and Gilead are hitting record highs. This flight to quality highlights the market's loss of confidence in growth narratives and its preference for stable cash flows and defensive positioning in an inflationary, recessionary environment.
Defensive Rotation to Biopharma
As the tech sector collapses, defensive rotation is accelerating into large-cap biopharmaceuticals. Eli Lilly received a price target raise to $1,500 from Wells Fargo, and shares of major drugmakers like J&J and Gilead are hitting record highs. This flight to quality highlights the market's loss of confidence in growth narratives and its preference for stable cash flows and defensive positioning in an inflationary, recessionary environment.